Anastrozole

Hormone Therapy
DB01217
Approved Indication

For adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in post-menopausal women. Has also been used to treat pubertal gynecomastia and McCune-Albright syndrome; however, manufacturer states that efficacy for these indications have

1 Targets
0 Resistance Mutations
6 References
3D Structure No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action

Anastrozole selectively inhibits aromatase. The principal source of circulating estrogen (primarily estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues. Therefore, aromatase inhibition leads to a decrease in serum and tumor concentration of estrogen, leading to a decreased tumor mass or delayed progression of tumor growth in some women. Anastrozole has no detectable effect on synthesis of adrenal corticosteroids, aldosterone, and thyroid hormone.

Details
DrugBank ID DB01217 ↗
Approval Date 1996-01-16
Molecular Weight 293.3663 g/mol
Drug Class Hormone Therapy
ATC Codes L02BG03
Synonyms Anastrozol
SMILES
CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
ADMET Profile
Computing properties…